Search results
Results from the WOW.Com Content Network
In 2012 ivacaftor was designated as an orphan drug, identifying cystic fibrosis as affecting fewer than 200,000 people in the United States.On 31 January 2012, Vertex gained FDA approval [22] of the first drug, Kalydeco, [23] to treat the underlying cause of cystic fibrosis rather than the symptoms, in patients 6 years or older who have the G551D gene mutation.
Jeffrey Leiden is an American physician, scientist and businessman who is the executive chairman of Vertex Pharmaceuticals, a biotechnology company based in Boston, Massachusetts. [1] He was initially appointed to the board of directors of the company in 2009 and was CEO and president from February 2012 to March 2020. [2] [3]
Reshma Kewalramani, is the president and chief executive officer of Vertex Pharmaceuticals, a biotechnology company based in Boston, Massachusetts, as of April 1, 2020. [1] [2] [3] She is the first female CEO of a large US biotech company. [2]
Vertex Pharmaceuticals sold the royalty it receives on hepatitis C drug Incivo to its longtime partner Janssen Pharmaceutical, a subsidiary of Johnson & Johnson , for $152 million, the company ...
Its latest report of clinical data suggests it has a winner on its hands.
Vertex Pharmaceuticals (NAS: VRTX) carries $802.8 million of goodwill and other intangibles on its balance sheet. Sometimes goodwill, especially when it's excessive, can foreshadow problems down ...
[3] [4] She then joined Vertex Pharmaceuticals as the chief scientific officer before becoming the senior VP of research and development and ultimately serving as the president of Vertex Pharmaceuticals from 2000 to 2005. During her tenure, the drugs Avonex, Tysabri, and Telaprevir were developed. [5] [6]
Vertex Pharmaceuticals (NASDAQ: VRTX) Q3 2024 Earnings Call Nov 04, 2024, 4:30 p.m. ET. ... Vertex's CEO and president; Stuart Arbuckle, chief operating officer; and Charlie Wagner, chief ...